#AHA20 – Randomized trial: In patients with systolic heart failure, Cardiac Myosin activation with Omecamtiv Mecarbil led to modest reduction in heart failure events

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries: Modest Gains With Omecamtiv Mecarbil in Chronic HFrEF: GALACTIC-HF – TCTMD AND Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure – GALACTIC-HF – American College of Cardiology

Commentary on Twitter

Among patients with heart failure & a reduced ejection fraction, those who received the cardiac myosin activator omecamtiv mecarbil had a lower incidences of heart-failure events or cardiovascular death at a median of 22 months than those who received placebo. #AHA20

— NEJM (@NEJM) November 13, 2020